Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Phase 2 Study of LTX-315 in Combination with Pembrolizumab in Patients with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy (… Ended

2022-500628-31-00 Advanced Melanoma 4 2022-10-24
A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS Ended

2024-516711-24-00 Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinom 7 2022-10-18
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI… Ended

2023-504270-38-00 In participants with PD-L1–positive and systemic therap 4 2022-10-18
Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended

2023-503529-20-00 BRCA Mutations and Early Stage HER2-Negative Breast Can 4 2022-10-17
A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors Ended

2023-508280-69-00 Advanced Malignant Tumors 1 2022-10-07
A Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Ewing's Sarcoma Ended

2023-506772-28-00 Ewings Sarcoma 4 2022-10-07
Comparative Bioavailability of Nilotinib 200 mg Hard Capsules in Healthy Subjects. Ended

2022-501325-20-00 Primary Philadelphia-chromosome positive leukemia cells 2 2022-10-06
Dose escalation trial of BNT152+153 in patients with cancer Ended

2023-509508-13-00 Various solid tumors that are metastatic or unresectabl 1 2022-10-04
Study of PIT565 in relapsed and/or refractory B-cell malignancies Ended

2023-507430-25-00 Relapsed and/or refractory B-cell Non-Hodgkin lymphoma 1 2022-10-03
Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study Ended

2024-513635-24-00 oesophageal cancer 10 2022-09-29
MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended

2023-503615-14-00 Relapsed or Refractory Classical Hodgkin Lymphoma 4 2022-09-29
Phase 1/2 Study of ZN-c3 and Niraparib and ZN-c3 Monotherapy in Platinum-Resistant Ovarian Cancer Ended

2024-515196-35-00 Platinum-Resistant Ovarian Cance 3 2022-09-29
Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melano… Ended

2024-519451-29-00 Uveal melanoma 4 2022-09-23
A study of Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme Ended

2024-517660-27-00 Glioblastoma multiforme (GBM) 4 2022-09-22
Study of tuvusertib (M1774) in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors Ended

2022-500287-35-00 Metastatic or Locally Advanced Unresectable Solid Tumor 3 2022-09-21
A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02) Ended

2024-513993-23-00 Patients with higher risk myelodysplastic syndrome (MDS 9 2022-09-21
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Ended

2023-504400-29-00 Advanced malignancies. 1 2022-09-15
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo… Ended

2024-511750-53-00 Unresectable Locally Advanced or Metastatic Cancer 7 2022-09-08
Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended

2024-510649-33-00 Advanced/metastatic hepatocellular carcinoma (HCC) 9 2022-09-02
TEMPLE - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Ended

2024-517307-37-00 Oncology 7 2022-09-01
A Study of SGN-B7H4V in Advanced Solid Tumors Ended

2023-503389-22-00 Fallopian tube cancer 1 2022-08-31
Efficacy and safety of UV1 vaccination +/- standard of care as first line treatment of patients with non-small cell lung cancer Ended

2022-502437-25-00 advanced or metastatic non-small cell lung cancer 4 2022-08-15
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Ended

2023-505425-14-00 colorectal cancer 9 2022-08-11